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Structural basis for the specificity of PPM1H
phosphatase for Rab GTPases
Dieter Waschb€usch1,† , Kerryn Berndsen2,3,† , Pawel Lis2,3 , Axel Knebel2, Yuko PY Lam2,3 ,
Dario R Alessi2,3,* & Amir R Khan1,4,**
Abstract
LRRK2 serine/threonine kinase is associated with inherited Parkin-
son’s disease. LRRK2 phosphorylates a subset of Rab GTPases
within their switch 2 motif to control their interactions with effec-
tors. Recent work has shown that the metal-dependent protein
phosphatase PPM1H counteracts LRRK2 by dephosphorylating
Rabs. PPM1H is highly selective for LRRK2 phosphorylated Rabs,
and closely related PPM1J exhibits no activity towards substrates
such as Rab8a phosphorylated at Thr72 (pThr72). Here, we have
identified the molecular determinant of PPM1H specificity for
Rabs. The crystal structure of PPM1H reveals a structurally
conserved phosphatase fold that strikingly has evolved a 110-
residue flap domain adjacent to the active site. The flap domain
distantly resembles tudor domains that interact with histones in
the context of epigenetics. Cellular assays, crosslinking and 3-D
modelling suggest that the flap domain encodes the docking motif
for phosphorylated Rabs. Consistent with this hypothesis, a PPM1J
chimaera with the PPM1H flap domain dephosphorylates pThr72
of Rab8a both in vitro and in cellular assays. Therefore, PPM1H has
acquired a Rab-specific interaction domain within a conserved
phosphatase fold.
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Introduction
Metal-dependent Ser/Thr phosphatases (PPMs) have a structurally
conserved catalytic domain that adopts a b-sandwich fold with
Mg2+/Mn2+ ions at the active site. Among the family of human
enzymes is PPM1A (formerly PP2Ca), which reverses stress-
mediated protein kinase cascades (Moore et al, 1991; Maeda et al,
1994; Chen et al, 2017), PHLPP1/2, which regulates AGC kinases
and cellular homeostasis (Grzechnik & Newton, 2016), and pyru-
vate dehydrogenase phosphatase (PDP1) that is expressed in the
mitochondrial matrix and regulates the activity of pyruvate dehy-
drogenase in metabolism (Linn et al, 1969; Vassylyev & Symersky,
2007). The core PPM fold, first identified by the structure of
PPM1A (Das et al, 1996), consists of an 11-stranded b-sandwich
flanked on both sides by a-helices (for recent reviews, see
Kamada et al (2020) and Gao et al (2021)). The catalytic cleft is
formed on one side of the b-sandwich and comprises a binuclear
Mg2+/Mn2+ metal centre that is coordinated by conserved aspartate
residues. The 250-residue PPM fold is better conserved in struc-
ture rather than sequence (20–50% identities) across the mamma-
lian enzymes. There is also considerable diversity among PPMs
involving the incorporation of sequence elements outside of the
catalytic domain. For example, PPM1A has a C-terminal a-helical
domain that is not required for catalysis but may contribute to
substrate specificity (Das et al, 1996; Stern et al, 2007; Debnath
et al, 2018). Several enzymes including PPM1A, PPM1B, PPM1K
and PDP1 also have a short 50-residue insertion termed the “flap”
subdomain that is poorly conserved in sequence and structure.
This region is predicted to contribute to substrate specificity,
although chimeric enzymes involving grafts of the flap have not
been successful in transferring substrate preference (Su & Forch-
hammer, 2013). Studies of bacterial enzymes have proposed a
third metal-binding site that contributes to catalysis via coordina-
tion with a conserved aspartate residue (Pullen et al, 2004; Ranta-
nen et al, 2007; Schlicker et al, 2008). Mutation of the equivalent
residue in human PPM1A to glutamate (D146E) enabled crystal-
lization of a complex of PPM1A with a cyclic phosphopeptide and
subsequent structure determination (Debnath et al, 2018).
Recently, PPM1H phosphatase has been identified as the
enzyme that counteracts the LRRK2 signalling cascade by dephos-
phorylating Rab GTPases (Berndsen et al, 2019). A subset of at
least 7 Rabs are physiological substrates of LRRK2 (Steger et al,
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2016, 2017) a Ser/Thr kinase that is associated with inherited and
sporadic forms of Parkinson’s disease (PD) (Alessi & Sammler,
2018; Di Maio et al, 2018). Rabs are members of the Ras super-
family of molecular switches that regulate membrane trafficking
in eukaryotes. Rabs oscillate between a membrane-bound GTP
form and cytosolic GDP form that is distinguished by local confor-
mational changes in nucleotide-sensitive switch 1 and switch 2
motifs (Hutagalung & Novick, 2011). LRRK2 phosphorylates Rab8a
and Rab10 at a conserved threonine residue in their switch 2 a-
helix (pThr72 in Rab8a and pThr73 in Rab10). Phosphorylated
Rab8a/10 (pRab8a/10) recruit phospho-specific effectors RILPL1
and RILPL2 (Rab-interacting lysosomal protein-like 1 and 2) to
subcellular compartments, downstream of LRRK2 activation. Auto-
somal dominant PD mutations that activate LRRK2 kinase inter-
fere with the formation of primary cilia through a pathway
involving pRab8a/10 binding to RILPL1 (Dhekne et al, 2018).
LRRK2 kinase inhibitors are currently in phase 1 and 2 clinical
trials with PD patients (Azeggagh & Berwick, 2021), while alterna-
tive strategies to antagonize LRRK2 signalling could be beneficial
for future therapeutics.
Here, we describe the crystal structure of PPM1H, a phos-
phatase that counteracts the LRRK2 pathway. The structure reveals
novel features that have been incorporated into the core catalytic
domain. The first is a 110-residue “flap domain” that is positioned
next to the catalytic cleft. This domain is an expansion of a 50-
residue flap that is found in other members of the PPM family. The
PPM1H flap domain adopts an a/b fold resembling tudor domains
that regulate histone functions in an epigenetic context. On the
opposite face of the cleft, a 3-stranded b-sheet motif (b-motif) is
also inserted into the core PPM fold. Thirdly, PPM1H has an N-
terminal extension that winds behind the active site and inserts
into the hydrophobic core of the b-sandwich. This anchor-like
interaction has apparently evolved in the PPM1H/J/M subfamily of
phosphatases as a motif that contributes to folding of the enzymes.
Mutagenesis, cellular assays, crosslinking and modelling studies of
a phospho-Rab substrate into the active site suggest that the
PPM1H flap domain forms a docking site for phosphorylated Rab
GTPases. In support of this hypothesis, transfer of the flap domain
of PPM1H onto PPM1J is sufficient to convert the PPM1J chimaera
into an active phospho-Rab8a phosphatase. Therefore, PPM1H
phosphatase has evolved substrate specificity through the acquisi-
tion of a Rab-specific flap domain within the framework of a
conserved catalytic domain.
Results
Overall structure of PPM1H phosphatase
Full-length PPM1H expressed in E. coli cells was unstable and
prone to degradation, thus difficult to crystallize. To design a crys-
tallisable protein, the N-terminal residues 1-32 were eliminated due
to predicted flexibility (Fig 1A). We also introduced a D288A muta-
tion (PPM1HDA) that destabilizes a third metal ion (Mg2+/Mn2+) at
the active site. Previous studies of PPM1A (D146A) showed that
this variant acts as a substrate-trapping mutant (Debnath et al,
2018). Crystals were grown of PPM1HDA that diffracted to 3.1 A
resolution (Table 1), but no crystals grew of the WT enzyme. To
grow WT crystals and improve diffraction, a “loop deletion” vari-
ant of PPM1H (PPM1H-LD) was designed to eliminate a flexible
and non-conserved loop (188-226) that was predicted to be distant
from the active site. WT and D288A variants of PPM1H
(PPM1HWT-LD, PPM1HDA-LD) diffracted to 2.5 A and 2.6 A resolu-
tion, respectively. The variants PPM1HDA, PPM1HWT-LD, and
PPM1HDA-LD have identical 3-D structures with two Mg2+ ions at
the active site. In addition to the Mg2+ complexes, a structure of
PPM1HWT (33-514, loopDEL) with 3 Mn2+ ions was also determined
at 2.2 A resolution (MnPPM1HWT-LD). The 2.5 A model of
PPM1HWT-LD will be used for ensuing discussions (Fig 1), except
for 3-D docking analyses with model substrates in which we used
the MnPPM1HWT-LD variant. However, all of the structures are
identical with only minor differences arising from flexible loops
and the presence or absence of the third metal ion at the active
site. Deletion of the loop 188-226 and the N-terminus (1–32) does
not affect the ability of PPM1HWT-LD to dephosphorylate pRab8a
relative to the full-length enzyme in vitro and in cells (Fig EV1A
and B). Statistics of data collection and refinement for all structures
are shown in Table 1.
The structure of PPM1H adopts a conserved PPM fold consisting
of 10 b-strands organized into a 5 × 5 b-sandwich (Fig 1B). The first
b-sheet comprises b-strands b2, b7, b8, b10 and b11. The second b-
sheet consists of b-strands b3, b4, b5, b6 and b9. Two a-helices pack
against each of the two concave surfaces of the b-sandwich. The
long and curved a-helices a1 and a2 are oriented in an anti-parallel
manner and pack against the second b-sheet. The shorter helices a4
and a5 are also oriented in an anti-parallel fashion and pack against
the first b-sheet. The active site cleft is formed by loops, including a
short a-helical loop (a4, residues 443–447), that connect b-strands
▸Figure 1. Structure of Rab-specific PPM1H phosphatase.A Domain organization of PPM1H, PPM1J and PPM1A. The annotation of regions (anchor, flap domain) is discussed in the text. The loop deletion (188–226) that was
engineered to improve diffraction is indicated.
B Ribbon model of the enzyme with a view to the catalytic cleft that contains two Mg2+ ions (cyan spheres). The N-terminal region is magenta (33–71), the flap domain
is a wheat colour, and the b-sheet motif is green. The loop deletion (188–226) connects a1/a2 on the opposite face relative to the active site. The back view of the
enzyme is also shown with a 180° rotation around the axis indicated. Parts of the anchor (RPxFL motif, magenta) that interact with the globular core are shown as
stick models, and discussed in the text. The b1 strand is orange to emphasize its non-canonical conformation due to the presence of the preceding anchor.
C Comparisons of the flap domain of PPM1H with PPM1A (left) and the tudor domain (right). Apart from a conserved loop (dotted circle) which forms an interface with
the catalytic domain, the sequences and structures of flaps are diverse among the PPM family.
D The indicated amounts of recombinant wild-type and mutant PPM1H or PPM1J (with a His-Sumo N-terminal tag, expressed in E. coli) were incubated in vitro with
2.5 µg pThr72-phosphorylated Rab8a (left) or pThr73-phosphorylated Rab10 (right) for 20 min in the presence of 10 mM MgCl2 in 40 mM HEPES pH 7.5 buffer.
Reactions were terminated by addition of SDS sample buffer and analysed by Phos-tag gel electrophoresis that separates phosphorylated (slow migrating) and
dephosphorylated Rabs. The gel was stained with Instant Blue Coomassie. D288A substrate-trapping (inactive) variant of PPM1H was used as a control.
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Table 1. PPM1H crystallographic data and refinement statistics.
PPM1HDA PPM1HWT-LD PPM1HDA-LD MnPPM1HWT-LD
Residues 33-514 33-514 (Δ188-226) 33-514 (Δ188-226) 33-514 (Δ188-226)
Crystallization 10% isopropanol, 5%
PEG4000, 0.05 M MgCl2
0.1 M imidazole pH 7, 20%
Jeffamine ED-2001
30% PEG1500, 0.1 M
MES pH 6.5
100mM Tris-Cl pH 8, 15% reagent
alcohol, 10mM MnCl2
Beamline NSLSII FMX NSLSII FMX NSLSII FMX APS 24-ID-E
Wavelength (A) 0.9789 0.9789 0.9789 0.97918
Space group P 21 21 21 P 21 21 21 P 21 21 21 P 21 21 21
Cell a, b, c, (A) 69.68, 102.16, 148.70 71.31, 102.4, 148.72 70.69, 101.11, 148.97 70.24, 101.04, 149.36
Resolution (A) 28.55–3.09 (3.20-3.09) 28.97–2.45 (2.54–2.45) 28.97–2.58 (2.68-2.58) 63.93-2.194 (2.272-2.194)
Unique reflections 19,927 (1,853) 39,279 (3,324) 34,031 (3,228) 54,665 (4,758)
Completeness (%) 99.25 (95.02) 98.28 (84.34) 99.42 (96.04) 98.42 (87.21)
<I/r> 19.83 (2.34) 14.6 (2.3) 16.79 (0.35) 12.72 (1.63)
Multiplicity 6.7 (6.3) 6.7 (6.7) 6.6 (6.5) 6.7 (6.7)
R-merge 0.070 (0.77) 0.08 (0.78) 0.0897 (0.673) 0.08947 (0.9865)
R-meas 0.076 (0.84) 0.086 (0.855) 0.097 (0.731) 0.09714 (1.068)
CC1/2 0.999 (0.855) 0.998 (0.779) 0.998 (0.847) 0.998 (0.764)
Refinement
Protein residues/waters/ions 794/14/4 793/115/4 794/91/4 785/211/8
No. reflections for R-free 1,003 (85) 1,968 (166) 1,708 (171) 2,485 (223)
R-work 0.1878 (0.3349) 0.1824 (0.2684) 0.1897 (0.2441) 0.1952 (0.2848)
R-free 0.2148 (0.4032) 0.2389 (0.3428) 0.2359 (0.2908) 0.2316 (0.3296)
RMSD bond lengths (A) 0.005 0.009 0.004 0.003
RMSD bond angles (°) 0.96 1.07 0.78 0.64
Average overall B-factor 98.78 61.03 57.65 57.06
Mean B-factors (A2) protein/
waters/ions
98.83/86.73/81.95 61.15/54.83/44.09 57.67/56.62/56.31 57.22/52.5/48.74
Ramachandran analysis
favoured/allowed (%)
94.63/4.48 95.5/3.86 96.53/3.08 97.41/2.33
PDB accession code 7kpr 7l4j 7l4i 7n0z
Values in parentheses correspond to the statistics in the highest resolution bin. RMSD, root mean square deviation. LD corresponds to the “loop deletion” variant
of PPM1H.
R-merge = Σhkl Σj∣Ihkl,j-<Ihkl>∣/Σhkl Σjhkl,j.
R-work = Σhkl∣Fo,hkl – Fc,hkl∣/ΣhklFo,hkl.
▸Figure 2. Crosslinking and docking analysis suggest that the flap domain binds to pRab8a.A SDS–PAGE analysis of the PPM1H(D288A): pRab8a complex in the presence of DSBU crosslinker. Control migration of proteins is on the left. NP, non-phosphorylated
Rab8a; P, phosphorylated Rab8a. The migration of control and crosslinked proteins is marked on the right.
B Crosslinked peptides from PPM1H and pRab8a are mapped onto the sequence. The flap domain forms extensive crosslinks with pRab8a. In addition, two flexible
loops (104–142, 188–226) also have multiple crosslinks with the substrate.
C Ribbon model of pRab8a (left) and the switch 2 phosphopeptide (right) docked onto the active site of PPM1H. The crosslinks shown between PPM1H and pRab8a are
within accepted distance constraints (32 A) for DSBU (He et al, 2015).
D Kinetics of phosphate hydrolysis. 25 nM recombinant wild-type PPM1H was incubated with increasing concentrations of pThr72-phosphorylated Rab8a (GTPcS or
GDP) as described in Materials and Methods. Initial velocity (V0) was calculated by dividing the concentration of released phosphatase (lM) by time (min) and plotted
against substrate concentration for pThr72-phosphorylated Rab8a [GTP-bound conformation] (blue) and pThr72-phosphorylated Rab8a [GDP bound conformation]
(red). The experiments were repeated twice, and both data points are shown in curves. Line fittings for the left and middle panels were performed using the mean of
the two values. Kinetic constants (Kcat, Vmax, Km) were obtained using GraphPad software, and their uncertainties () correspond to the SE of mean.
E Kinetic analysis of PPM1H as in (D) using 50 nM PPM1H and phosphopeptide substrates, as described in Materials and Methods. Initial velocity (V0) was calculated
by dividing the concentration of phosphatase (lM) by time (min) and plotted against substrate concentration for pThr72-Rab8a phosphopeptide (blue) and pThr73-
Rab10 phosphopeptide (red). Each experiment was performed twice (individual data points shown).
F Side-by-side comparison of the catalytic activity against protein and peptide by in vitro malachite green time course analysis. 50 nM recombinant wild-type PPM1H
was incubated with 16 lM Rab8a GTPcS pThr72-phosphorylated protein (blue) or Rab8a pThr72-phosphorylated peptide (red) for indicated times and analysed as
described in Materials and Methods. The experiments were repeated 3 times. The error bars represent SE of mean of the technical replicates.
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on one edge of the b-sandwich. Three conserved aspartate residues
—D151, D437 and D498—form direct contacts with two Mg2+ ions
(M1 and M2) at the active site. M1 is coordinated by D437 and
D498, while D151 coordinates both metal sites. The metal binding
includes water molecules, and the geometry is approximately octa-
hedral for both metal sites (M1 and M2). A structure-based
sequence alignment of PPM1H against human enzymes with known
3-D structures is shown to emphasize common and divergent
features of the PPM family (Fig EV1C).
One of the distinctive features of PPM1H is a 110-residue flap
domain that adopts an a/b fold (Fig 1C). All known structures of
human PPMs (PPM1A, PPM1B, PPM1K and PDP1) have a shorter
50-residue flap that is inserted between the terminal b-strands of
the two b-sheets (b8 and b9 in PPM1H). In PPM1H, this domain
comprises an a-helix that stacks against a highly twisted b-sheet.
This extended flap domain effectively creates a surface adjacent to
the active site for potential substrate recognition. Matching of the
flap domain to structures in the DALI server (Holm, 2020) reveals
a resemblance to the tudor domain despite the absence of
sequence similarities (Fig 1C). Tudor domains are also composed
of an a-helix that stacks against a highly twisted anti-parallel b-
sheet. These domains are involved in the recognition of methy-
lated lysine or arginine residues of histones via an aromatic cage.
Although roughly similar in appearance, the a/b flap domain of
PPM1H has a different topology and lacks characteristic structural
motifs such as the aromatic cage that are common to tudor
domains. Despite flap sequence and structural diversity among
the PPM family, a short loop 386-396 that packs against the cata-
lytic domain is highly conserved in sequence and conformation
(dotted circle, Fig 1C). This conserved loop is investigated in more
detail below.
Compared to structures of other known enzymes, PPM1H has
two additional structural elements that are novel. The N-terminal
residues 33-79 follow an irregular path behind the active site
that spans the two b-sheets of the core catalytic domain
(Fig 1B). This region is termed an “anchor” due to a short 310
helix (residues 43-47) that caps the hydrophobic core of the
b-barrel. The second feature is a b-sheet motif (b-motif; residues
480-496) that consists of 3 short anti-parallel b-strands. These
novel features of PPM1H, along with an expanded flap domain,
are shared by the PPM1H/J/M subfamily of phosphatases. The
specificity of PPM1H against PPM1J was compared over a 20-
min reaction at room temperature using catalytic amounts of
enzyme. These in vitro assays used Phos-tag gels (Ito et al,
2016) to assess dephosphorylation of phospho-Rab8a (pRab8a)
and phospho-Rab10 (pRab10) substrates (Fig 1D). Despite shar-
ing common domains, PPM1J displays no activity, while PPM1H
completely dephosphorylates pRab8a and pRab10 under these
conditions.
Crosslinking and 3-D docking suggest that the PPM1H flap is a
pRab recognition domain
Purified complexes of pRab8a and the substrate-trapping D288A
variant of PPM1H were incubated together in the presence of DSBU
(disuccinimidyl dibutyric urea), a mass spectrometry cleavable
amine reactive crosslinker that is widely used to identify and map
sites of protein–protein interactions (Pan et al, 2018). This reagent
crosslinks Lys residues to acidic and hydroxyl amino acids located
within 32 A (Götze et al, 2019). In the presence of DSBU, pRab8a
and PPM1H formed a stoichiometrically heavier band on
Coomassie-stained gels migrating at ~140 kDa (Fig 2A). The
crosslinking was dependent on phosphorylation of Thr72, since the
heavier band failed to form with PPM1H/Rab8a or PPM1H alone
incubations. The size of the crosslinked species implied 2 molecules
of PPM1H (50 kDa each) and 2 molecules of pRab8a (20 kDa each)
in solution. Consistent with dimeric complexes of the enzyme,
crosslinked PPM1H alone migrated as a dimer (100 kDa) and
further information below is supportive of PPM1H being a dimer.
Crosslinked samples were digested under 3 conditions (trypsin,
trypsin/AspN and trypsin/GluC). In addition, SCX cartridge purifica-
tion was applied in one of the tryptic digested samples to further
enrich the crosslinked peptides. PPM1H and pRab8a crosslinked
peptides were identified using meroX software (Götze et al, 2012).
Potential crosslinked peptides with score higher than 50, as well as
false discovery rate (FDR) < 5%, were manually inspected to
◀ Figure 3. PPM1H is a dimer.
A Model of the dimeric form of MnPPM1HWT-LD. Each monomer of PPM1H has an A or B prefix. Flap domains mediate the dimer and are shown in dark blue/wheat
colours. The view is down a pseudo-twofold formed by a3 in the flap domain. Dotted lines denote the flexible loop (183–235) that connects a1/a2 in the catalytic
domain. The dimeric organization of PPM1H positions this loop next to substrates, shown as docked models of pRab8a in green ribbons (transparent). The
phosphorylated switch 2 helix of pRab8a is red. Yellow spheres indicate site of a double mutation in the flap domain (G357E+A359E) that disrupts a contact with a2
of the catalytic domain.
B SEC-MALS analyses of PPM1HWT-LD and PPM1H2Glu-LD, showing that the WT enzyme is a dimer (104.5  2 kDa) while the double mutant is a
monomer (53.6  1 kDa). The calculated molecular weight of His6-tagged PPM1HWT-LD used for the experiment is approximately 52.1 kDa. The errors
were calculated from the SE of technical replicates from the data represented as a line across the central peaks in the gel filtration column. Light
scattering from 15/18 possible angles (DAWN-EOS, Wyatt Corp) and the refractive index change relative to buffer (Optilab TrEX) were collected every
second along these time points. Subsequently, data were processed using Astra 7.1 software (Wyatt Corp) to generate a weight-averaged molecular mass
(y-axis) plotted against time (x-axis). There were approximately 130 technical data points for PPM1HWT-LD and 60 technical data points for
PPM1H2Glu-LD.
C His6-SUMO-tagged full-length variants of PPM1H were used for catalytic assays (left panel). 3 lg of recombinant wild-type or indicated mutant PPM1H proteins were
resolved on 4–12% Bis–Tris gradient gel and stained with Instant Blue Coomassie. Right, mass photometry histogram for 40nM His6-SUMO-PPM1H WT (blue) and
His6-SUMO-PPM1H 2Glu (brown), where WT is 130 kDa ( 15.8 kDa, with 1,004 single molecules counted) and 2Glu is 83 kDa ( 13.9 kDa, with 4,117 single
molecules counted). The calculated molecular weight of the fusion protein is approximately 68.5 kDa.
D In vitro malachite green assay time course of recombinant His6-SUMO-tagged PPM1H wild-type (blue), 2Glu (red) or D288A (grey) against 16 lM pThr72-
phosphorylated Rab8a protein (GTPcS, left), 32 lM pThr72-phosphorylated Rab8a peptide (middle) or 32 lM pThr73-phosphorylated Rab10 peptide (right). The
experiments were repeated 4 times. The error bars represent SE of mean of the technical replicates.
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confirm only a single crosslinked site was proposed from each
peptide (Iacobucci et al, 2018). This protocol identified numerous
residues within the flap domain of PPM1H that were crosslinked to
pRab8a (Fig 2B; also see “Data Availability” section). Interestingly,
other regions in PPM1H that formed significant crosslinks with
pRab8a were situated in likely more flexible regions namely the N-
terminal non-catalytic region, and within the 104-142 and 183-235
flexible loops (Fig 2B). These data are consistent with the flap
domain of PPM1H functioning as a major substrate recognition site
for pRab8a.
In order to further understand the mode of pRab8a interactions
with PPM1H, docking analyses were performed. Phosphorylated
Rab8a (pRab8a, GTP-bound) from the recent structure of the
pRab8a:RILPL2 complex (Waschb€usch et al, 2020) was docked
onto PPM1H using Haddock software (Dominguez et al, 2003; van
Zundert et al, 2016). The structure of MnPPM1HWT-LD with 3
Mn2+ ions was used for docking with distance restraints applied
between pThr72 of pRab8a and the metal ions of PPM1H. The
structures of PPM1H with two Mg2+ ions failed to dock with
pRab8a at the active site, presumably due to the density of nega-
tive charges in the absence of a third metal ion. The top pRab8a
docking solution is shown along with the experimentally deter-
mined crosslinks from the flap domain (Fig 2C). The model reveals
that the extended active site cleft involving the flap domain forms
multiple interactions with pRab8A within the PPM1H active site.
Overall, the crosslinking data and docking model are consistent
with pRab8a recognition by the flap domain with phosphorylated
Thr72 in the switch II motif oriented towards the active site for
dephosphorylation.
We also performed docking of the switch 2 a-helical peptide
from pRab8a with MnPPM1HWT-LD. The 15 residue fragment from
65 to 79 was extracted from the structure of the pRab8a complex,
and the N/C termini were capped (acetyl/amide) to eliminate
charges. The docking solutions were more heterogeneous and
many poses would be sterically incompatible with the active site in
the context of the full G domain of phospho-Rabs. However, two
of the top 10 solutions revealed a similar orientation of the phos-
phorylated switch 2 helix to the protein/protein dock (Fig 2C).
Overall, the complete 8/10 docking solutions of PPM1H/peptide
and the top 5/6 docking solutions of PPM1H/protein suggest that
the flap domain is very likely to contribute to substrate recognition
(Fig EV2A and B).
PPM1H dephosphorylates pRab8a both in the GDP and GTP states
It is unknown whether PPM1H dephosphorylates pRab8a in its GTP
or GDP state. To address this question, we generated pRab8a
complexed to GDP or GTPcS and undertook Km/Vmax kinetic analy-
ses (Fig 2D). This revealed that PPM1H dephosphorylated both the
GDP and GTP pRab8a with moderately different kinetics. PPM1H
dephosphorylated the GDP-pRab8a complex with a Km of 24 lM
and a Vmax of 3.0 lM/min, and GTPcS – pRab8a complex with a Km
of 14 lM and a Vmax of 1.4 lM/min. Therefore, the Vmax is doubled
for the GDP complex, but the GTPcS complex is dephosphorylated
with an ~40% lower Km. This suggests that PPM1H in vivo would
be able to act on both the GTP and GDP states of pRab proteins. The
kinetic parameters for Thr72/Thr73-phosphorylated switch 2
peptides from Rab8a and Rab10 (pRab8a=AGQERFRT*ITTAYYR;
pRab10=AGQERFHT*ITTSYYR; residues differing between the two
peptides are underlined) that encompass residues 65–79 of human
Rab8a/10 (Rab8a numbering) were also determined (Fig 2E). The
relatively high Km values for peptides (Rab8a = 134 lM;
Rab10 = 47 lM) suggest that they are not optimal substrates
compared with the G domain of pRabs. In a side-by-side comparison
of substrates assayed at 16 lM, pRab8a (GTPcS) is sevenfold more
efficient as a substrate in early time points (5-10 min) relative to the
peptide variant (Fig 2F). As a control, there was no significant
PPM1H hydrolysis of GTPcS and GDP from non-phospho Rab
complexes under the conditions of these assays (Fig EV2C).
PPM1H is a dimer
The asymmetric unit in all 4 structures is a dimer that is facilitated
by interactions between a3 of the flap domains, as well as contacts
between the flap domain (residues 356–360) and a2 of the catalytic
domain (Fig 3A). Given the observed dimeric state of PPM1H with
DSBU crosslinker, we explored the oligomerization state of the
enzyme in solution. Using size exclusion chromatography coupled
to multi-angle light scattering (SEC-MALS), we showed that
PPM1HWT-LD is a dimer (Fig 3B). In order to determine whether the
contacts observed in crystals enable dimerization in solution, resi-
dues Gly357 and Ala359 were mutated to glutamate residues. The
double mutant PPM1H2Glu-LD would be predicted to introduce
longer side chains and negative charges that disrupt packing against
a2 of the partner PPM1H molecule (Fig 3A). SEC-MALS analyses of
◀ Figure 4. The flap domain of PPM1H is a determinant of Rab specificity.
A Domain organization of chimeric variants for in vitro and cellular assays.
B 3 lg of recombinant proteins were resolved on 4–12% Bis–Tris gradient gel and stained with Instant Blue Coomassie.
C In vitro malachite green assay time course to determine enzyme activity of 25 nM recombinant PPM proteins against 16 lM pThr72-phosphorylated Rab8a protein
(GTPcS). The experiments were repeated 3 times. The error bars represent SE of mean of the technical replicates.
D In vitro malachite green assay to determine enzyme activity of 50 nM recombinant PPM proteins against 32 lM pThr72-Rab8a peptide (left) and pThr73-Rab10
peptide mimic (right). The experiments were repeated 3 times. The error bars represent standard error (SE) of mean of the technical replicates.
E, F (E) HEK293 cells overexpressing indicated constructs were treated with  200 nM MLi-2 for 90 min and then lysed. 10 lg whole cell lysate was subjected to
immunoblot analysis with the indicated antibodies at 1 lg/ml final concentration, and membranes were analysed using the OdysseyClx Western Blot imaging
system. Left, each lane represents cell extract obtained from a different dish of cells (two biological replicates per condition without MLi-2 treatment, one biological
replicate per condition with MLi-2 treatment). Right, the ratio of phospho-Rab8a/total Rab8a was quantified using Image Studio software and data presented
relative to the phosphorylation ratio observed in PPM1H wild-type expressing cells. (F) As in (E) assessing phospho-Rab10 levels. For quantitation, the two
replicates from the presented blots were used. The data points are shown on the graphs with the bar levels representing the mean value of the biological
replicates.
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PPM1H2Glu-LD revealed that it is indeed a monomer as designed
(Fig 3B). The apparent physiological dimer can accommodate two
Rab substrates without steric conflicts (Fig 3A). A potential PPM1H:
pRab8A heterotetrameric complex would be organized with a
twofold symmetry axis parallel to the a3 helices in the flap domain
(Fig 3A).
Full-length PPM1H proteins fused to His6-SUMO at their N-
termini were generated to probe whether the dimer is important for
catalytic activity in vitro. The newly developed method of mass
photometry was initially used to determine the oligomeric state of
purified proteins in solution (Young et al, 2018). His6-SUMO-
PPM1HWT was observed to be a dimer at 40nM concentration, while
the His6-SUMO-PPM1H
2Glu variant (in which residues Gly357 and
Ala359 in the flap domain were both mutated to Glu) was a
monomer (Fig 3C). The enzymatic activity of the monomeric vari-
ant of PPM1H was evaluated using pRab8a (GTPcS) and phospho-
peptides from Rab8a and Rab10 (Fig 3D). Relative to WT, the
monomeric variant of PPM1H appeared to be moderately more
active against pRab8a protein. However, the catalytic activity of
monomeric PPM1H was indistinguishable from the dimer using
peptide substrates (Fig 3D). Therefore, the monomeric enzyme is
active and dimerization is not required for efficient catalytic activity
in vitro.
PPM1J chimaeras with the PPM1H flap domain are active
against pRab8a
Although PPM1J is a close relative of PPM1H, previous work
revealed negligible activity towards LRRK2 phosphorylated Rabs in
cellular or biochemical assays (Berndsen et al, 2019). Ignoring loops
that are predicted to be unstructured and distant from the active site
cleft, PPM1H and PPM1J have an identical domain organization
(Figs 4A and EV3A). Intriguingly, residues in the catalytic domain
of PPM1J that would face towards the substrate cleft are highly
conserved and unlikely to account for specificity (Fig EV3B). The
flap domains of PPM1H/J have relatively high sequence identities,
but several sites that face the catalytic cleft are divergent (Figs EV3B
and C). To broadly explore the determinants of specificity, we engi-
neered PPM1J chimaeras that adopt the PPM1H anchor and/or flap
domain (Figs 4A and B). The sequences of the chimeric proteins are
provided in Zenodo repository file (https://doi.org/10.5281/zenodo.
5045023). The structure of PPM1H was critical for guiding the sites
for grafts and thereby maintaining the integrity of the core catalytic
fold. These recombinant proteins were successfully purified, and
their catalytic properties were evaluated. Strikingly, the PPM1J
chimaeric proteins adopting the PPM1H flap domain were markedly
active towards the pRab8a protein displaying similar or even moder-
ately enhanced activity than PPM1H (Fig 4C). We also noted that
the PPM1J chimaera proteins containing the PPM1H flap domain
restored activity towards the pRab8a peptide substrates (Fig 4D).
This indicates that a portion of the PPM1H flap domain is also
contributing to the interaction with the peptide. PPM1J displayed
detectable but low activity towards the Thr72-phosphorylated Rab8a
peptide. In contrast, the PPM1J chimaera possessing the PPM1H N-
terminal anchor gained a moderate level of activity against both
pRab8a peptide and protein substrates, suggesting a minor contribu-
tion of the PPM1H anchor towards pRab8a specificity. Full activity
for the J/H double chimaera also suggests that the anchor regions of
PPM1H/J can be swapped without effects on catalysis and that the
flap domain is the dominant factor in specificity. Grafting of the
PPM1J flap onto PPM1H (H/J flap) abolished the catalytic activity
against pRab8a peptide and protein substrates (Fig 4C and D). We
also analysed the activity of chimaeras using Thr73-phosphorylated
Rab10 peptides (Fig 4D, right panel). The peptide mimic of pRab10
is more promiscuous since it is dephosphorylated by PPM1J, albeit
at a lower rate than PPM1H. Here again substitutions with the
PPM1H flap/anchor motif stimulated the rates at which PPM1J
dephosphorylated the pRab10 peptide. We also analysed the activity
of PPM1M in these assays and observed that PPM1M displays low
but detectable activity towards pRab8a GTPcS as well as the pRab8a
and pRab10 phosphopeptide substrates (Fig 3D).
We further explored the activity of chimaeric proteins in cellular
assays. Lysates of HEK293 cells overexpressing pathogenic LRRK2
[R1441G], Rab8a, and wild-type or mutant forms of PPM1H were
immunoblotted using pThr72-Rab8a phospho-specific antibody
(Fig 4E). These assays reveal that PPM1J chimaeras that adopt the
PPM1H flap domain, in contrast to wild-type PPM1J, dephosphory-
late pRab8a to nearly the same extent as wild-type PPM1H (Fig 4E).
We also repeated these experiments with Rab10 instead of Rab8a
and found that the PPM1J chimaeras that adopt the PPM1H flap
domain partially dephosphorylate Rab10, but to an intermediate
level compared with PPM1H expressing cells (Fig 4F). Overall, these
results suggest that for cellular assays the gain of function by intro-
ducing PPM1H anchor and flap domains into PPM1J is less striking
◀ Figure 5. Mutagenesis and functional assays identify determinants of catalysis.
A Sites for targeted mutagenesis on the flap domain and active site Lys88 residue. The central ribbon model provides context for the conserved loop (left) and epitopes
distant from the active site in the flap domain (right). Residues subjected to mutagenesis are shown as stick models, with dotted envelopes in the central panel for
emphasis. Docked pRab8a (yellow ribbons, right) highlights its proximity to mutated residues in the flap domain. The sequences of the conserved loop motif are
shown below the left panel for several PPMs with known 3-D structures (PPM1H, PPM1K, PPM1B, PPM1B).
B In vitro malachite green assay time course of recombinant PPM1H mutants against 16 lM pThr72-phosphorylated Rab8a protein (GTPcS, left), 32 lM pThr72-
phosphorylated Rab8a peptide (middle) or 32 lM pThr73-phosphorylated Rab10 peptide (right). The experiments were repeated 4 times. The error bars represent SE
of mean of the technical replicates.
C 3 lg of recombinant wild-type or indicated mutant PPM1H proteins were resolved on 4–12% Bis–Tris gradient gel and stained with Instant Blue Coomassie.
D HEK293 cells overexpressing indicated constructs were treated and analysed as described in Fig 4E.
E Activity of 25 nM PPM1H flap domain mutants against 16 lM pThr72-phosphorylated Rab8a protein (GTPcS) using the malachite green assay time course. The
experiments were repeated 3 times. The error bars represent SE of mean of the technical replicates. Quality of purified proteins (right panel) is shown using the
protocol in (C).
F HEK293 cells overexpressing indicated constructs were treated and analysed as described in (D), with pRab10 analysed in the upper panel, and pRab8a in the lower
panel.
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than in vitro. It is possible that additional factors such as cellular
localization of PPM1H mutants regulate catalytic function in cells.
Grafting the flap domain of PPM1J onto PPM1H resulted in marked
loss of function in cellular assays of pRab8a and pRab10 hydrolysis
(Fig 4E and F). Altogether, the in vitro and cellular assays suggest
that the flap domain of PPM1H is an important determinant of
substrate specificity for Rab GTPases.
Mutagenesis and enzymatic assays of PPM1H
From the crosslinking and modelling studies, we identified Arg338
as a potential site of pRab8a binding despite being situated 27 A
from the catalytic ions (Fig 5A). In addition, a loop in the flap
domain (386–396), with Leu392 at its centre, forms an interface
with a2 and the b-sandwich of the catalytic domain (Met252,
Ala271, Cys269, Ile256). Despite the diversity of flap conformations
among the PPM family, a short motif in this loop is highly
conserved in sequence and structure, and therefore, it was targeted
for mutagenesis. Finally, a lysine residue (Lys88) was identified,
which is conserved as Arg33 in PPM1A (Fig EV1B) and is predicted
to bind directly to the phosphate moiety of substrates (Debnath
et al, 2018). Thus, three distinct sites were initial targets for mutage-
nesis and subsequent functional assays.
We firstly evaluated the impact of the K88A and R338A muta-
tions in a quantitative biochemical time course assay using either
pThr72-Rab8a complexed to GTPcS as a substrate (Fig 5B, left) or
pRab8a/pRab10 phosphopeptide substrates (Fig 5B, middle/right).
For these assays, full-length PPM1H variants with an N-terminal
HIS6-SUMO tag were purified (Fig 5C). Although there were impuri-
ties in these preparations, their levels relative to intact enzyme were
similar among the WT and mutants. The exception was L392A
whose low yield of intact enzyme precluded quantitative analyses.
The assays revealed that the PPM1H[K88A] mutation reduced initial
rate activity by over 20-fold using both protein and phosphopeptide
substrates. This is consistent with Lys88 playing a key role in medi-
ating a direct contact with phospho-threonine of substrates. The
R338A mutation reduced PPM1H initial activity approximately
twofold when assayed with the pRab8a protein (Fig 5B, left), but
had no significant impact when assayed with pRab8a/10 peptides
(Fig 5B, middle/right). This result is consistent with Arg338 in the
flap domain contributing towards optimal docking of pRab8a
protein substrate, but not the peptide.
Using the HEK293 cell assay, we next investigated the role of the
conserved loop from the flap domain, which forms an interface with
the catalytic core (Fig 5D). The L392A mutant was expressed at
twofold to threefold lower levels compared with wild-type and
displayed reduced activity towards phosphorylated Rab10. We also
generated a quadruple mutant (L392A+D394A+H395A+D396A) that
eliminates several interactions simultaneously between the loop and
the catalytic domain. When expressed in HEK293 cells, this quadru-
ple mutant lacked detectable activity towards phosphorylated Rab10
and was expressed ~3-fold lower levels than wild-type PPM1H
(Fig 5D). Therefore, this conserved loop in the flap domain likely
contributes to folding and may also affect catalysis. We also
assessed the impact of K88A and R338A mutations in the HEK293
cell assay and observed that both mutations were expressed at
comparable levels to wild-type and displayed reduced ability to
dephosphorylate pRab10. The significance of the mutant
P44A+F46A+L47A (Fig 5D) is discussed below in the context of the
“anchor” region of PPM1H.
In addition to the above mutations, we identified potential Rab-
interacting sites in the flap domain that is not conserved in PPM1J
(Figs 5A and EV3C). We generated three mutants of PPM1H—
Y374C, H400C+D401S, and Q340L+R341P+D365L—which converted
PPM1H residues to their PPM1J counterparts in the flap domain.
Although the wild-type and recombinant proteins show partial
degradation, they all retain catalytic activity against pRab8a
(Fig 5E). A corresponding cellular assay involving these mutants
similarly revealed no significant reduction in catalytic activity
against either pRab8a or pRab10 substrate (Fig 5F). The reverse
mutations in the flap domain (C365Y, C391H+S392D,
L331Q+P332R+L356D) were also generated on a PPM1J background
to see whether these sites enabled a gain-of-function phenotype.
However, cellular assays revealed no significant activity against
pRab8a and pRab10 (Fig 5F). These observations suggest that the
specificity of PPM1H for Rab substrates does not localize to a single
dominant epitope in the flap domain.
Anchor-like folding motif in the PPM1H/J/M subfamily
PPM1H possesses a novel N-terminal extension preceding the core
catalytic domain (Fig 6A). S33 interacts with the C-terminus of a2,
adjacent to the flap domain, before winding around the back of the
enzyme to the opposite side of the b-sandwich. PPM1A and PDP1
have an additional b-strand (b1) at the edge of the first b-sheet. In
PPM1H, part of this anti-parallel b1 strand is conserved, while the
remainder is dislodged and forms a loop preceding a shortened b2
strand. This distinct b1 strand conformation of PPM1H is due to the
presence of a short 310 helix (residues 43–47) in the N-terminal
extension. The 310 helix facilitates the insertion of the aromatic ring
of F46 into the hydrophobic core of the b-sandwich (Fig 6A).
Resembling an “anchor”, the side chains of P44, F46, and L47 cap
the hydrophobic core of the b-barrel, effectively substituting for
strand b1. To probe its significance, systematic deletion of the N-
terminal residues of PPM1H towards the 310 helix was performed
(Fig 6B). Strikingly, PPM1H is relatively active until R43 is deleted
◀ Figure 6. Anchor of PPM1H is a folding motif.
A Interactions between the anchors of PPM1H against the electrostatic surface of the core catalytic domain. The region is placed in context with the dotted box on a
ribbon model of PPM1H (right).
B Incremental deletions of the N-terminal 37 to 44 residues, one residue at a time. Upon deletion of R43 (44-end), a reduced level of soluble PPM1H expression has no
significant catalytic activity.
C Sequence alignment of the N-terminal regions of the evolutionarily related PPM1H/J/M enzymes. The degree of conservation is above the alignment, and residue
numbers correspond to PPM1H. A conserved anchor motif (RPxFL) is annotated below the sequences.
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(construct 44-end), which leads to reduced expression in HEK293
cells and loss of activity towards LRRK2 phosphorylated Rab10. To
probe the importance of residues comprising the 310 helix, we
mutated P44, F46 and L47 to alanine and observed that this
nearly abolished PPM1H soluble expression in HEK293 cells,
emphasizing their importance for enzyme folding (Fig 5D). Immedi-
ately following the 310 helix, an a-helix (aN, N51-A58) and loop
(D59-I65) interact directly with an active site loop (V83-D94).
Despite sequence diversity at their N-termini, the PPM1H/J/M
subfamily of phosphatases have a conserved RPxFL motif (Fig 6C).
This anchor motif is likely involved in the folding of the catalytic
domain through hydrophobic interactions with the b-sandwich. It
may also influence catalysis due to its protrusion against the active
site and a tether-like connection between the flap domain and the
b-motif.
Discussion
The PPM family of phosphatases have a common catalytic domain
with the incorporation of diverse structural elements that facilitate
their specificity and function. The flap is adjacent to the active site
and poorly conserved in sequence and structure within the PPM
family. It has been associated with substrate specificity and catalysis
(Chin-Sang & Spence, 1996; Schlicker et al, 2008), but previous
chimaeras involving the flap region have been unsuccessful in trans-
ferring functions (Su & Forchhammer, 2013). Here, we provide
evidence that PPM1H phosphatase specificity for Rab GTPases is
encoded by the flap domain. Substitution of this domain into PPM1J
leads to its ability to hydrolyse phospho-Rab8a both in vitro and in
cellular assays. Also, we have identified a highly conserved loop
motif from the flap domain (residues 386–396) that appears to
contribute to folding and/or catalysis. This conserved loop in
human PPMs, with Leu392 at its centre (PPM1H numbering), has
not been investigated previously. Although speculative, we think it
might couple substrate binding to catalysis given its proximity to
the active site. Intriguingly, the equivalent Leu392 hydrophobic
pocket has recently been identified as a “regulatory switch” in
bacterial phosphatases (Bradshaw et al, 2017). Finally, an anchor
preceding the catalytic domain caps the hydrophobic core of the b-
sandwich and has apparently evolved as a folding motif in the
PPM1H/J/M subfamily. In a PPM1J chimaera, the PPM1H anchor
and flap domain act in concert to promote the dephosphorylation of
pRab8a and pRab10. A cartoon model depicting the structural
Figure 7. Model of PPM1H specificity for Rab GTPases.
Although PPM1H phosphatase is likely to be dimeric in cells, a 1:1 complex is shown for simplicity. The switch 2 helix is red and the phosphate site is yellow. The flap
domain (305–414) encodes the primary specificity for phosphorylated Rabs, while the anchor (33–79) contributes to folding of the enzyme. The b-motif (green, residues
480–496) is also indicated. The conserved loop motif (386–396) with a central Leu392 residue may couple substrate binding to catalysis.
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attributes that encode PPM1H specificity for phospho-Rab GTPases
is shown in Fig 7. Although extended flap domains are conserved in
evolutionarily related PPM1J and PPM1M, differences in the
sequence and/or conformation of PPM1H flap likely encode the
specificity for phosphorylated Rab8a/10. Further details of PPM1H
specificity await the structure of a substrate-trapped complex.
We also find that PPM1H is a physiological dimer in solution via
contacts mediated by the flap domain. DSBU-induced crosslinks
between a flexible loop 183-235 and pRab8a can be attributed to
dimerization. This loop is distant from the active site, but in a
docked model of a heterotetrameric complex, this PPM1H loop is
situated in close proximity to pRab8a at the active site of the dimeric
partner (Figs 2B and 3A). At least one of the residues in this loop
(Ser210) is phosphorylated (Osawa et al, 2020), and in future stud-
ies, it would be important to investigate the role that dimerization
plays in controlling PPM1H function in cells. However, conversion
of the enzyme into a monomer by mutagenesis through abolition of
flap/a2 contacts does not markedly affect catalysis in vitro. PPM1H
has been localized to Golgi, where it likely counters the LRRK2 path-
way by dephosphorylating Rab8a and Rab10 under physiological
conditions (Berndsen et al, 2019). Rab proteins have a flexible
stretch of  30 residues between their G domain and their preny-
lated C-terminal tails that localize them to subcellular membranes
(Fig 7). In future work, it would be important to dissect the mecha-
nism by which PPM1H localizes to membranes to hydrolyse phos-
phorylated Rab substrates.
Materials and Methods
Reagents and Tools table
Reagent/Resource Reference or source Identifier or Catalog Number
Recombinant DNA
HA-Empty MRC-PPU Reagents DU44059
FLAG-LRRK2 [R1441G] MRC-PPU Reagents DU13077
HA-Rab10 MRC-PPU Reagents DU44250
HA-PPM1H WT MRC-PPU Reagents DU62789
HA-PPM1H [H153D] MRC-PPU Reagents DU62928
HA-PPM1H [D288A] MRC-PPU Reagents DU62985
HA-PPM1H loopDEL MRC-PPU Reagents DU68360
HA-PPM1H loopDEL [D221A] MRC-PPU Reagents DU68361
HA-PPM1H [F46A] MRC-PPU Reagents DU68435
HA-PPM1H [P44A/F46A/L47A] MRC-PPU Reagents DU68463
HA-PPM1H [K88A] MRC-PPU Reagents DU68433
HA-PPM1H [R338A] MRC-PPU Reagents DU68422
HA-PPM1H [L392A] MRC-PPU Reagents DU66371
HA-PPM1H [L392A/D394A/H395A/D396A] MRC-PPU Reagents DU66380
HA-PPM1H [D394A] MRC-PPU Reagents DU61295
HA-PPM1H [H395A] MRC-PPU Reagents DU61297
HA-PPM1H [D396A] MRC-PPU Reagents DU61298
HA-PPM1H 62-end MRC-PPU Reagents DU68393
HA-PPM1H 74-end MRC-PPU Reagents DU68394
HA-PPM1J WT MRC-PPU Reagents DU68077
HA-PPM1J/H Double Chimera MRC-PPU Reagents DU70010
HA-PPM1H 38-end MRC-PPU Reagents DU61258
HA-PPM1H 39-end MRC-PPU Reagents DU66542
HA-PPM1H 40-end MRC-PPU Reagents DU66546
HA-PPM1H 41-end MRC-PPU Reagents DU66543
HA-PPM1H 42-end MRC-PPU Reagents DU66544
HA-PPM1H 43-end MRC-PPU Reagents DU66545
HA-PPM1H 44-end MRC-PPU Reagents DU61350
HA-PPM1H 45-end MRC-PPU Reagents DU61260
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Reagents and Tools table (continued)
Reagent/Resource Reference or source Identifier or Catalog Number
HA-PPM1H/J Flap chimera MRC-PPU Reagents DU70606
HA-PPM1J C365Y MRC-PPU Reagents DU68819
HA-PPM1J C391H+S392D MRC-PPU Reagents DU68820
HA-PPM1H L331Q+P332R+L356D MRC-PPU Reagents DU68850
HA-PPM1H Y374C MRC-PPU Reagents DU68825
HA-PPM1H H400C+D401S MRC-PPU Reagents DU68826
HA-PPM1H Q340L+R341P+D365L MRC-PPU Reagents DU68852
HA-PPM1J/H Flap chimera MRC-PPU Reagents DU68622
HA-PPM1J/H Anchor Chimera MRC-PPU Reagents DU68626
6HIS-SUMO-PPM1H WT MRC-PPU Reagents DU62835
6HIS-SUMO-PPM1H [K88A] MRC-PPU Reagents DU68559
6HIS-SUMO-PPM1H [R338A] MRC-PPU Reagents DU68554
6HIS-SUMO-PPM1H [D288A] MRC-PPU Reagents DU68087
6HIS-SUMO-PPM1H [L392A] MRC-PPU Reagents DU68560
6HIS-SUMO-PPM1J WT MRC-PPU Reagents DU68140
6HIS-SUMO-PPM1J/H Double chimera MRC-PPU Reagents DU70009
6HIS-SUMO-PPM1J/H Anchor chimera MRC-PPU Reagents DU68625
6HIS-SUMO-PPM1J/H Flap chimera MRC-PPU Reagents DU68621
pET15b-MST3 TV2 MRC-PPU Reagents DU62878
pET28a(+)-PPM1HD288ALoopDEL This study N/A
pET28a(+)-PPM1HWTLoopDEL This study N/A
pNIC28-Bsa4-PPM1H33-514D288A This study N/A
pLIC-MBP-PPM1H1-514WT This study N/A
pET15b-PPM1J57-505 This study N/A
pET15b-Rab8a1-181Q67L This study N/A
Antibodies
Anti-HA (clone 3F10) (Rat IgG1) Sigma-Aldrich 11867423001
Anti-phospho-Rab10 (Thr73) (Rabbit monoclonal) Abcamd #ab23026
Anti Rab10 (mouse monoclonal) Nanotools 0680-100/Rab10-605B11
Anti-LRRK2 (mouse monoclonal) Neuromab 75-253
Anti-phospho-LRRK2 (Ser935) (rabbit monoclonal) MRC PPU UDD2
Methods and Protocols
Constructs and expression of proteins
Information about the expression constructs from the MRC-PPU
repository at the University of Dundee is reported on the https://
mrcppureagents.dundee.ac.uk/ website. DNA constructs were
amplified in Escherichia coli DH5a and purified using a Hi-Speed
Plasmid Maxi Kit or mini-prep kits (Qiagen).
The cDNA for PPM1HDA-LD (residues 33-514, D288A) with the
residues 188-226 replaced by a short GSGS motif was synthesized as
a codon-optimized gene for E. coli expression (GenScript, Inc). The
cDNA was cloned into pET28a-(+)-TEV at the NdeI/BamH1 restric-
tion sites. The PPM1HWT-LD construct was made by site-directed
mutagenesis using the following primers: 50-GTG GCG AAC GCG
GGT GAT AGC CGT GCG ATC ATT ATC-30 (for) and: 50-GAT AAT
GAT CGC ACG GCT ATC ACC CGC GTT CGC CAC-30 (rev). Full-
length and 57-end cDNA variants of PPM1J were obtained from
GenScript with codon-optimization for E. coli expression. Using
NdeI and BamH1 sites at their 50 and 30 ends, the genes were
inserted into the same vector above. The PPM1HDA (residues 33–
514) construct was amplified using the following primers: 50-
TACTTCCAATCC TCG GAC CTG CCC CTG CGT TTC30 (for) and 50-
TATCCACCTTTACTG TTA TCA TGA CAG CTT GTT TCC ATG-30
(rev); S33(PPM1H)/stop codons underlined. We used a human
PPM1H (NM_020700) template carrying the D288A mutation and
LIC cloned the resulting DNA into the pNIC28-BSA4 vector which
allows the expression of a hexahistidine-tagged protein. All plasmids
generated by PCR were confirmed by sequencing. For the full-length
PPM1H PhosTag assay, residues 1–514 of PPM1H were LIC cloned
into the pLIC-MBP vector (Cabrita et al, 2006). The primers used to
amplify PPM1H from the template pET15b-Sumo-PPM1H (Univer-
sity Dundee DU62790) were as follows: 50-C CAG GGA GCA GCC
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TCG ATG CTC ACT CGA GTG AAA TC-30 (for) and 50-GC AAA GCA
CCG GCC TCG TTA TCA TGA CAG CTT GTT TCC-30 (rev).
Expression of PPM1H was carried out in LB Broth supplemented
with 30 lg/ml kanamycin (FORMEDIUMTM). After incubation at
37°C to an OD600 of ~0.6, the culture was cooled down to 18°C and
induced with 0.5 mM IPTG (FORMEDIUMTM), after which cells were
grown at 18°C overnight. Cells were harvested by centrifugation,
and the pellets were resuspended in His-tag extraction buffer
(20 mM Tris–HCl pH 8.0, 300 mM NaCl, 5 mM MgCl2, 20 mM
imidazole and 10 mM b-mercaptoethanol). Purification of PPM1H
in complex with Mn2+ involved substitution of MgCl2 with MnCl2 in
all steps. After lysis by sonication, the cell lysate was centrifuged at
26,000 g for 45 min at 4°C to remove cellular debris. The super-
natants were loaded onto a nickel agarose resin (QIAGEN) in a grav-
ity flow setup. The resin was washed with a 10-fold excess of
extraction buffer and fivefold excess wash buffer (extraction buffer
supplemented with 40 mM Imidazole). The hexahistidine-tagged
protein was then eluted using extraction buffer supplemented with
200 mM imidazole.
In the case of proteins for crystallization removal of the His6 tag
was performed by overnight incubation at 4°C in dialysis against gel
filtration buffer (20mM Tris–HCl pH 8.0, 100 mM NaCl, 5 mM
MgCl2, 1 mM DTT) using recombinant TEV protease, followed by a
second Ni2+-agarose column. The “flow-through” fractions were
collected, while the uncut proteins remained on the resin. Soluble
aggregates were eliminated by running the sample through a
Superdex 200 (10/300) gel filtration column (GE Healthcare) equili-
brated in gel filtration buffer. The peak fractions of PPM1H were
pooled and concentrated in 10 kDa MWCO concentrator tubes prior
to crystallization trials. A detailed protocol describing the expression
and purification of PPM1H has been reported (https://doi.org/10.
17504/protocols.io.bu7wnzpe).
Phosphorylation of Rab8a Q67L and Rab10 Q68L
The in vitro phosphorylation of Rab8a (T72) by MST3 kinase and
subsequent purification has been described previously (Waschb€usch
et al, 2020) and a detailed protocols.io protocol reported (https://
doi.org/10.17504/protocols.io.butinwke). In brief, Rab8a was mixed
with MST3 at a 8:1 molar ratio and incubated overnight. The phos-
phorylation buffer was adjusted to the following conditions: 50 mM
Tris–HCl, 150 mM NaCl, 10 mM MgCl2, 2 mM ATP, pH 7.5. The
phosphorylation mixture was then dialysed against low salt buffer
and loaded to a MonoS (GE Healthcare) column. Phosphorylated
Rab8a was separated from unphosphorylated by ion exchange chro-
matography applying a 50% gradient low to high salt buffer
(10 mM MES, 10 mM (low) or 1 M NaCl (high), 5 mM MgCl2,
1 mM DTT, pH 5.2). The phosphorylation of Rab8a was confirmed
by PhosTag gel electrophoresis prior to subsequent experiments.
pRab10 was prepared by phosphorylating Rab10 (1-181) by MST3
using a similar procedure described previously (https://doi.org/10.
17504/protocols.io.bvjxn4pn).
Crystallization, data collection and refinement
Crystals of PPM1H variants were grown at concentrations between 5
and 10 mg/l using the vapour diffusion method. Crystals were
harvested in precipitant supplemented with 30% glycerol and stored
frozen in liquid nitrogen. X-ray data were collected under a cryo-
genic nitrogen stream (100 K) at the FMX beamline, NSLSII
synchrotron (Brookhaven, New York, USA). Details of crystallization
conditions and the quality of diffraction data are shown in Table 1.
Native diffraction data were reduced using XDS and Aimless,
followed by structure determination using the Phaser software in the
PHENIX package (McCoy et al, 2007; Adams et al, 2010). Molecular
replacement using Phaser (PPM1A; PDB code 6b67 (Debnath et al,
2018)) was successful using data from crystals of PPM1HDA-LD, and
subsequently, Autobuild in Phenix provided an initial model for
PPM1H. Refinement was performed through multiple rounds of
energy minimization and model building using Phenix and Coot soft-
ware (Emsley et al, 2010). The structures of the other variants of
PPM1H (PPM1HWT, PPM1HWT-LD, MnPPM1HWT-LD) were deter-
mined using PPM1HDA-LD as a search model and subsequently
refined using Phenix and Coot. These higher resolution models were
useful for the final refinement of PPM1HWT-LD. To reduce model
bias, all four structures have common reflections flagged for the R-
free data set. PPM1HWT-LD, PPM1HDA-LD and MnPPM1HWT-LD
have a single cysteine mutation (C56A) at a non-conserved residue
that enhances crystallizability. The asymmetric unit for all structures
contains two molecules of PPM1H. Two non-native residues (His-
Met) from the cleaved affinity tag are seen in one of the molecules of
PPM1HDA-LD at its N-terminus. There is residual density at the
active site of MnPPM1HWT-LD which does not resemble any obvious
solutes such as alcohol, phosphate ions and glycerol. Therefore, it
has been modelled as water molecules. Statistics from data collection
and refinement are shown in Table 1.
Docking of PPM1H and pRab8a
Docking was performed using Haddock software (van Zundert et al,
2016) with distance restraints between the active site of PPM1H and
pThr72 of pRab8a (Waschb€usch et al, 2021; Data ref: Waschb€usch
& Khan, 2021). Initial attempts at docking of PPM1H variants with
two Mg2+ ions resulted in solutions with > 7 A distance between the
metal ions and the switch 2 phosphate of pRab8a. More realistic
distances between the active site and pRab8a were achieved using
the structure of MnPPM1HWT-LD, including a direct contact (3 A)
between the third metal site (M3) and pThr72. No other distance
restraints between the enzyme and substrate were applied to enable
an unbiased docking calculation. The structures were stripped of
waters and refined with explicit solvent followed by default CNS
scripts (Crystallography and NMR System) that performed semi-
flexible simulated annealing and docking calculations. Docking of
the switch 2 phosphopeptide (residues 65–79) was performed by
extracting the coordinates from the structure of pRab8a. The
N-terminus was capped by an acetyl group while the C-terminus
was capped by an amide to eliminate charges. Docking calculations
were performed using the same strategy outlined for the G domain
of pRab8a.
Cell culture, transfections, treatment and lysis
HEK293 cells were cultured in Dulbecco’s modified Eagle medium
(Gibco) supplemented with 10% (v/v) foetal bovine serum, 100 U/
ml penicillin and 100 µg/ml streptomycin at 37°C and 5% CO2.
Cells used in this study were regularly tested for mycoplasma
contamination. Transient transfections were performed 24 h prior to
cell lysis using polyethylenimine PEIMax (0.1% w/v) (Polysciences)
(Longo et al, 2013). Cells were grown to ~70% confluency in 6-well
(3.5 cm well diameter) plates prior to transfection. 1.75 lg total
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plasmid DNA was mixed with 5.5 ll PEI in 150 ll Opti-MEM I
Reduced Serum Media (Gibco) and incubated for 30 min at room
temperature. The DNA-PEI mixture was added drop-wise to cells.
Cells were treated  MLi-2 LRRK2 inhibitors (Fell et al, 2015) at a
final concentration of 200 nM 90 min prior to lysis. Cells were lysed
in 150 ll ice-cold lysis buffer (50 mM Tris–HCl pH 7.5, 150 mM
NaCl, 10% glycerol, 10 mM 2-glycerophosphate, 10mM sodium
pyrophosphate, 1 mM sodium orthovanadate, 1 lg/ml microcystin-
LR, complete EDTA-free protease inhibitor cocktail (Roche) and 1%
(v/v) Triton X-100) and collected in 1.5-ml Eppendorf tubes. Lysates
were clarified by centrifugation at 20,800 g at 4°C for 20 min, and
supernatants were quantified by Bradford assay before subjected to
immunoblot analysis.
Immunoblot analysis
Clarified cell or tissue extracts were mixed with a quarter of a
volume of 4× SDS–PAGE loading buffer [250 mM Tris–HCl, pH 6.8,
8% (w/v) SDS, 40% (v/v) glycerol, 0.02% (w/v) Bromophenol Blue
and 4% (v/v) 2-mercaptoethanol]. 10 µg of samples was loaded onto
NuPAGE 4–12% Bis–Tris Midi Gel (Thermo Fisher Scientific, Cat#
WG1403BOX) and electrophoresed at 130 V for 2 h with the
NuPAGE MOPS SDS running buffer (Thermo Fisher Scientific, Cat#
NP0001-02). At the end of electrophoresis, proteins were elec-
trophoretically transferred onto the nitrocellulose membrane (GE
Healthcare, Amersham Protran Supported 0.45 µm NC) at 100 V for
90 min on ice in the transfer buffer (48 mM Tris–HCl and 39 mM
glycine). Transferred membrane was blocked with 5% (w/v) skim
milk powder dissolved in TBS-T [20 mM Tris–HCl, pH 7.5, 150 mM
NaCl and 0.1% (v/v) Tween 20] at room temperature for 1 h. The
membrane was typically cropped into three pieces, namely the “top
piece” (from the top of the membrane to 100 kDa), the “middle
piece” (between 100 and 37 kDa) and the “bottom piece” (from
37 kDa to the bottom of the membrane). The top piece was incu-
bated with rabbit anti-LRRK2 pS935 UDD2 antibody multiplexed
with mouse anti-LRRK2 C-terminus total antibody diluted in 5%
(w/v) bovine serum albumin in TBS-T to a final concentration of
1 µg/ml for each of the antibody. The middle piece was incubated
with rat anti-HA antibody diluted in 5% (w/v) bovine serum albu-
min in TBS-T to a final concentration of 100 ng/ml. The bottom
pieces were incubated with mouse anti-GAPDH multiplexed with
rabbit MJFF-pRab10-clone-1 monoclonal antibody and rat anti-HA
antibody diluted in 5% (w/v) bovine serum albumin in TBS-T to a
final concentration of 0.5 µg/ml for each of the antibodies. All blots
were incubated in primary antibody overnight at 4°C. Prior to
secondary antibody incubation, membranes were washed three
times with TBS-T for 10 min each. The top and bottom pieces were
incubated with goat anti-mouse IRDye 680LT (#926-68020)
secondary antibody multiplexed with goat anti-rabbit IRDye 800CW
(#926-32211) secondary antibody diluted in TBS-T (1:25,000 dilu-
tion) for 1 h at room temperature. The middle piece was incubated
with goat anti-mouse IRDye 800CW (#926-32210) secondary anti-
body diluted in TBS-T (1:25,000 dilution) at room temperature for
1 h. Membranes were washed with TBS-T for three times with a 10-
min incubation for each wash. Protein bands were acquired via near
infrared fluorescent detection using the Odyssey CLx imaging system
and quantified using the Image Studio software. A detailed proto-
cols.io protocol for immunoblotting LRRK2 and pRabs has previously
been described (https://doi.org/10.17504/protocols.io.bsgrnbv6).
Escherichia coli expression and purification of
recombinant phosphatases
Plasmids (DU62835; DU68087; DU68140; DU68554; DU68559;
DU68560; DU68621; DU68625; DU68875, DU70009, DU68875,
DU70609, DU68822, DU68823, DU68851, DU68828, DU68829,
DU68853, DU68141 all available from MRC-PPU Reagents: mrcp-
pureagents.dundee.ac.uk) were transformed into Escherichia coli
BL21-DE3-pLysS and expressed in 3 × 1 litre of Lucia Broth medium
(Merck) supplemented with 100 lg/ml ampicillin (Formedium).
Bacteria were cultured at 37°C until OD600 reached 0.8. The temper-
ature was reduced to 16°C, and after 1 h, protein phosphatase
expression was induced by addition of 25 lM Isopropyl b-D-1-
thiogalactopyranoside for incubation overnight. Cells were
harvested by centrifugation at 4,200 g for 30 min at 4°C before
being resuspended in 20 ml collection buffer (50 mM Tris–HCl pH
7.5, 150 mM NaCl, 20 mM imidazole, 2 mM MgCl2, 7 mM 2-
mercaptoethanol). The resuspension was made to 5% (by vol) glyc-
erol, 300 mM NaCl, 0.4% Triton X-100, 1 mM AEBFS (Pefabloc)
and 10 lg/ml Leupeptin. Cell suspension was sonicated, and insol-
uble material was removed by centrifugation at 40,000 g at 4°C for
25 min. 2 ml Cobalt resin was equilibrated in collection buffer
before incubated with lysates for 2 h at 4°C. After incubation, resin
was washed 5 times with 7 volume wash buffer (50 mM Tris–HCl
pH 7.5, 250 mM NaCl, 20 mM imidazole, 2 mM MgCl2, 7 mM 2-
mercaptoethanol, 5% (v/v) glycerol). The resin was transferred
onto a 5 ml polyprep (Bio-Rad) filtration device. Protein was eluted
with elution buffer (wash buffer diluted with 1 M imidazole to
0.4 M imidazole), and 1 ml fractions were collected. Protein-
containing fractions were pooled, and 1.6 ml protein was subjected
to size exclusion chromatography using a Superdex 200 XK16/60
column (GE Healthcare) and equilibrated into 50 mM Tris–HCl pH
7.5, 200 mM NaCl, 2 mM MgCl2, 7 mM 2-mercaptoethanol, 0.015%
(w/v) Brij35. Fractions containing PPM1H were pooled and concen-
trated before aliquoted and snap-frozen to store at 80°C. A detailed
protocols.io protocol for expression and purification of PPM1H has
been reported (https://doi.org/10.17504/protocols.io.bu7wnzpe).
Quality control gel for recombinant phosphatases
A total of 3 lg of each protein was prepared in SDS–PAGE sample
buffer and 5% 2-mercaptoethanol. Electrophoresis was carried out
using NUPAGE Bis–Tris 4–12% gradient gels (Life Technologies) and
run at 120 V. The gel was then stained for 1h using Instant Blue
Coomassie (Expedeon). Protein concentrations were adjusted using the
upper protein band, which corresponded to the undegraded protein.
Quantitative phosphatase assays
The quantitatively Thr72-phosphorylated Rab8a complexed to either
GTP or GDP was prepared as described previously (Berndsen et al,
2019). The phosphopeptide encompassing the Thr72 LRRK2 phos-
phorylation site on human Rab8a (AGQERFRT*ITTAYYR residues
65–79, where T* – pThr) was synthesized and purified by JPT Peptide
Technologies GmbH. Phosphate release from either the phospho-
Rab8a protein or peptide was detected by using the malachite green
phosphatase assay (Baykov et al, 1988) according to the sigma proto-
col. The phosphatase assays were performed in 96-well flat-bottomed
plates using a final volume of 80 µl and either 25 nM PPM phos-
phatase and 16 lM phospho-Rab8a protein or 50 nM PPM phos-
phatase and 32 lM phospho-Rab peptide. The phosphatase was
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diluted in 50 mM Tris–HCl pH 7.5, 200 mM NaCl, 2 mM MgCl2,
7 mM 2-mercaptoethanol, 5% (v/v) glycerol. The phospho-Rab8a
protein and phosphopeptide are diluted in 40 mM HEPES buffer
pH7.5, supplemented with 10 mMMgCl2 at a final reaction volume of
80 ll. The reactions were undertaken at room temperature and initi-
ated by adding the diluted phosphatase to the phospho-Rab8 protein
or phosphopeptide substrate. At the indicated times, the reactions
were quenched by addition of 20 ll Malachite Green working reagent
(Sigma-Aldrich; MAK307). After incubation at room temperature for
30 min absorbance was measured at 620 nm. Free phosphate at
increasing concentrations (1–40 lM) was used to make a standard
curve, which was used to determine the concentration of phosphate
released from each reaction. Malachite green working reagent and
free phosphate standards were prepared fresh prior to each experi-
ment, according to Sigma manual. Graphs were prepared using
GraphPad Prism 5 software. To determine Km and Vmax of PPM1H
against pRab8a protein and pRab8a/pRab10 peptide substrates, phos-
phatase reactions were performed as described above, except that the
concentrations of phospho-Rab8a protein (complexed to either GDP
or GTPcS) were varied between 2 and 32 lM, and for the pRab8a or
pRab10 phosphopeptides between 2 and 256 lM. The initial rate (V0)
was calculated by dividing concentration of released phosphate at
5 min by time and plotted against each substrate concentration.
Enzyme kinetic constants were then obtained using GraphPad Prism
5 software. A detailed protocols.io protocol for quantifying PPM1H
phosphatase activity towards LRRK2 phosphorylated Rab proteins
and peptides using the Malachite Green method has previously been
reported (https://doi.org/10.17504/protocols.io.bustnwen).
Phostag PPM1H/PPM1J phosphatase assay with phospho-Rab8a
and phospho-Rab10
In vitro dephosphorylation assay was performed in a total volume
of 20 µl in 40 mM HEPES buffer (pH 7.0) containing 10 mM
MgCl2 using 2.5 µg pThr72-phosphorylated Rab8a or pThr73-
phosphorylated Rab10 and increasing concentrations of the phos-
phatase. The assay was initiated by addition of PPM1H or PPM1J (3,
10, 30, 100, 300 ng) diluted into 40 mM HEPES Buffer pH 7.5 supple-
mented with 10 mM MgCl2. The assay was carried out for 20 min
and terminated by addition of 4 × LDS (106 mM Tris–HCl, 141 mM
Tris Base, 2% (by mass) LDS, 10% (by vol) glycerol, 0.51 mM
EDTA, 0.22 mM SERVA Blue G250, 0.175 mM Phenol Red, pH 8.5)
with 5% (by vol) 2-mercaptoethanol. Samples were then subjected
to Phos-tag gel electrophoresis to determine stoichiometry of phos-
phorylated Rab8a or Rab10 as described previously in Ito et al
(2016). Gel was stained using Instant Blue Coomassie (Expedeon).
Mutagenesis, biophysical and functional studies of
monomeric PPM1H
The cDNA for PPM1H2Glu-LD (residues 33–514, G357E+A359E) was
synthesized as a codon-optimized gene for E. coli expression
(GenScript, Inc). The protein sequence is identical to PPM1HWT-LD
except for the double mutation that carries two glutamate residues
in the flap domain. WT and mutant variants were purified as
described above in extraction buffer supplemented with 5 mM
MgCl2. Following elution from Ni-agarose, the His6-tagged proteins
were immediately purified on a Superdex 200 (10/300) column. The
main peaks were collected for subsequent characterization using a
SEC-MALS system comprising an Agilent HPLC system coupled to a
DAWN Heleos multi-angle light scattering system and an Optilab
TrEX refractometer (Wyatt Corp). WT and mutant samples were
injected at 2 mg/ml concentration (100 ll) into a Superdex 200
column preceding the two detectors. Peaks were analysed using
Astra software (Wyatt Corp) to calculate the mass of PPM1H in solu-
tion. Astra data files have been uploaded to the Zenodo server
(https://doi.org/10.5281/zenodo.5045023).
Crosslinking of PPM1H and pRab8a
Recombinant PPM1H[D288A] phosphatase (purified as described in
https://doi.org/10.17504/protocols.io.bu7wnzpe) and recombinant
stoichiometrically Thr72-phosphorylated Rab8a (purified as
described in https://doi.org/10.17504/protocols.io.butinwke) were
used to perform the crosslinking analysis using DSBU crosslinker
(Pan et al, 2018). As the crosslinking reaction can be inhibited by
amine containing buffers, a buffer exchange step was performed for
both PPM1H and pRab8a protein solutions prior to the crosslinking.
Proteins were be dialysed into 40 mM HEPES pH 7.5, 150 mM NaCl,
2 mM MgCl2 buffer using Diacon dialysis tubes (MD6-71, Molecular
Dimensions). To form the complexes, a mixture of stoichiometri-
cally Thr72-phosphorylated Rab8a at a concentration 35 µM
(~0.7 mg/ml, migrates at 20 kDa) and PPM1H at 28 µM (~1.4 mg/
ml, migrates at 50 kDa) was prepared in total volume of 15.5 µl
using 40 mM HEPES pH 7.5, 150 mM NaCl, 2 mM MgCl2 as a dilu-
tion buffer (1.25-fold molar excess of Rab8a to PPM1H) and incu-
bated at 30°C for 1 h, and cooled down to RT for 10 min. A fresh
300 mM stock solution of the crosslinker was prepared by dissolv-
ing 1 mg of DSBU in 15.5 µl of anhydrous DMSO. An aliquot of the
crosslinker solution (0.5 µl) was added into 15.5 µl of the protein
solution and mixed, which resulted in a final concentration of
9.375 mM of DSBU (disuccinimidyl dibutyric urea, Thermo Scien-
tificTM, A35459) in 16 µl of reaction mix, giving a 250-fold molar
excess to pRab8a and 335-fold molar excess to PPM1H. The
crosslinking reaction was performed at RT for 10 min and quenched
by addition of 2 µl of 1 M Tris pH 8.8, followed by addition of 7 µl
of 4 × NuPAGE LDS sample buffer (without reducing agents). The
samples were immediately resolved by SDS–PAGE using a 4–12%
gradient NuPAGE Bis–Tris gel. The final reaction volume was 25 µl,
which allowed to run 6 µl of the sample 4 times, to use 4 different
digestion conditions. After the SDS–PAGE run, the gel was fixed and
stained for 2 h using InvitrogenTM Colloidal Blue Staining Kit and de-
stained in Milli-Q water (following the kit manual).
Selected bands were excised from the gel, cut into 1 mm cubes,
and placed in low-binding 1.5-ml Eppendorf tubes. Gel pieces were
dehydrated by addition of 500 µl of acetonitrile (ACN) and incuba-
tion for 10 min at RT. Supernatant was discarded and the samples
were reduced by adding 50 µl of freshly prepared 10 mM DTT solu-
tion and incubating at 56°C for 30 min with mixing (1,200 rpm).
After this incubation, 500 µl of ACN was added and the samples
were incubated at RT for 10 min. Supernatant was discarded, and
the samples were alkylated by adding 50 µl of freshly prepared
55 mM iodoacetamide (IAA) solution and incubating at RT for
20 min with mixing (1,200 rpm). After this incubation, 500 µl of
acetonitrile was added and the samples were incubated at RT for
10 min. Supernatant was discarded, and 100 µl of 50 mM ammo-
nium bicarbonate (ABC) in 50% (v/v) acetonitrile was added and
the samples incubated at RT for 30 min. After this incubation, 500 µl
of ACN was added and the samples were incubated at RT for 10 min;
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supernatant was discarded. Fresh solutions of proteases were
prepared: trypsin at a concentration of 50 ng/µl, AspN at a concen-
tration of 20 ng/µl, GluC at a concentration of 50 ng/µl. 20 µl of
Trypsin solution was added to the dehydrated gel pieces. For the
double-digestion conditions, 20 µl of AspN solution or 20 µl of GluC
solution was added following the addition of trypsin. Overnight
digestion at 30°C was performed. Peptides were eluted from gel
pieces twice using 100 µl of 1.67% (v/v) trifluoroacetic acid (TFA)
in acetonitrile, incubating at 37°C for 15 min with mixing
(1,200 rpm) each time. Supernatants were combined in 1.5-ml low-
binding Eppendorf tubes, frozen on dry ice and vacuum dried.
Enrichment of crosslinked peptides with MCX SPE cartridges
One of the tryptic digested samples from each experimental set (Rab-
8A, PPM1H and mixture of Rab-8A and PPM1H) was re-dissolved in
1 ml aqueous solution containing 4% (v/v) H3PO4. Samples were
then sonicated in water bath for 30 min. MCX cartridge was used to
enrich the crosslinked peptides according to the previous protocol
(Iacobucci et al, 2018). The MCX cartridges were first washed with
2 ml MeOH, then re-conditioned with 2 ml aqueous solution
containing 4% (v/v) H3PO4 prior to sample loading. Samples were
then individually loaded onto the MCX cartridges, followed by wash-
ing with 500 µl aqueous solution containing 4% (v/v) H3PO4 and
500 µl of 10% (v/v) MeOH solution with 0.1% (v/v) formic acid
(FA). Low-charged peptides were removed by 500 µl solution
composed of 500 mM NH4OAc in 40% (v/v) MeOH solution with
0.1% (v/v) FA. High-charged peptides were eluted by 700 µl solution
containing 2,000 mM NH4OAc in 80% (v/v) MeOH solution with
0.1% (v/v) FA. The eluted samples were further dried by SpeedVac.
LC MS/MS analysis of crosslinked peptides
All dried samples were resuspended in 30 µl solution containing 3%
(v/v) ACN and 0.1% FA, and further sonicated in water bath for
30 min. Liquid chromatography tandem mass spectrometry (LC
MS/MS) experiment was performed on an UltiMate 3000 RSLC
nano-HPLC system coupled to an Orbitrap ExplorisTM 480 mass spec-
trometer. 3–14 µl solution from each sample was loaded onto the
nano-HPLC system individually. Peptides were trapped by a
precolumn (Acclaim PepMapTM 100, C18, 100 µm × 2 cm, 5 µm,
100 A) using aqueous solution containing 0.1% (v/v) TFA. Peptides
were then separated by an analytical column (PepMapTM RSLC C18,
75 µm × 50 cm, 2 µm, 100 A) at 45°C using a linear gradient of 1 to
35% solvent B (solution containing 80% ACN and 0.1% FA) for
90 min, 35 to 85% solvent B for 5 min, 85% solvent B for 10 min,
85% to 1% solvent B for 1 min and 1% solvent B for 14 min. The
flow rate was set at 300 nl/min for all experiments. Data were
acquired with data-dependent MS/MS mode. For each MS scan, the
scan range was set between 375 and 1,500 m/z with the resolution
at 120,000 and 300% automatic gain control (AGC) was used. The
maximum injection time for each MS scan was 100 ms. The 10 high-
est abundant peptides with charge state between 2 and 8 as well as
intensity threshold higher than 1.0e+4 were then isolated with a
1.2 Da isolation window sequentially. Stepped HCD with normal-
ized collision energy of 27, 30 and 33% was applied to fragment the
isolated peptides. For each MS/MS scan, the resolution was set at
15,000 with a normalized AGC at 200%. The maximum injection
time was set at 250 ms. Dynamic exclusion with 60-s duration and
2 ppm window was enabled for the experiment.
Identification of crosslinked PPM1H/pRab8a peptides
The .RAW files obtained from the LC MS/MS experiments were
converted into .mgf files using RawConverter software (He et al,
2015). The .mgf files were submitted to search using MeroX soft-
ware against PPM1H and Rab8a protein sequences to identify
potential crosslinked peptides (He et al, 2015; Sonn-Segev et al,
2020). Digestive enzyme, trypsin, trypsin and AspN, or trypsin
and GluC, were selected according to the experimental setup. 3
maximum missed cleavages with peptide length ranged from 3 to
50 were applied. Carbamidomethylation at cysteine residues was
set as fixed modification, while oxidation at methionine residue
and deamidation at asparagine residue were included in variable
modification. DSBU crosslinker was selected with specificity cross-
linked sites at lysine, serine, threonine and tyrosine residues. 10
and 20 ppm were used to filter the mass error in precursor ion
(MS1) and fragment ion (MS2) scans. Only ions with signal-to-
noise ratio high than 2 were used for database search. RISEUP
searching mode was applied; minimum 2 fragments per peptide
and 5% false discovery rate (FDR) were required for a crosslinked
peptide identification. Potential crosslinked peptides with score
higher than 50 were then manually check to guarantee the cleav-
age information obtained from the MS experiment could identify
only a single crosslinked site in a peptide. A detailed protocol
describing the crosslinking and mass spectrometry analysis
methodology has been reported (https://doi.org/10.17504/protoc
ols.io.bv2en8be).
Mass photometry analyses of PPM1H
Mass photometry was performed using OneMP mass photometer
(Refeyn Ltd, Oxford, UK) and data acquisition performed using
AcquireMP (Refeyn Ltd, Oxford, UK). Microscope coverslips (No.
1.5, 24 × 50, VWR) and Grace Bio-Labs reusable CultureWellTM
gaskets (3 mm × 1 mm, well capacity 3–10 ll, Sigma-Aldrich,
GBL103250-10EA) were cleaned 3 times sequentially in 100%
isopropanol and Milli-Q H2O, followed by drying with a stream of
compressed air. The gasket was carefully placed and pressed onto
the centre of the coverslip to assemble the chamber. Prior to mass
photometry measurements, protein marker (NativeMark Unstained
Protein Standard, LC0725, Thermo Fisher) was diluted 50× in the
working buffer (40 mM HEPES pH 7.5). To find focus, 15 ll of
buffer was first pipetted into the well, and the focal position was
identified as described in the manual. 2.5 ll of protein marker was
pipetted into the same well containing the working buffer. A movie
of 10,000 frames was recorded, and distribution peaks of the protein
standards were fitted with Gaussian functions to obtain the average
molecular mass of each distribution component and used to gener-
ate the standard curve. Protein stocks were diluted in working
buffer to 40 nM final concentration in final volume of 15 ll. For
each acquisition, the diluted protein was pipetted into a new well
and movies of 10,000 frames were recorded. Each sample was
measured least three times. Images were analysed using Disco-
verMP (Refeyn Ltd, Oxford, UK).
Data availability
The structures of PPM1H phosphatase have been deposited in the
Protein Data Bank with codes 7kpr (https://www.rcsb.org/struc
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ture/7KPR; PPM1HDA), 7l4j (https://www.rcsb.org/structure/7L4J;
PPM1HWT-LD), 7l4i (https://www.rcsb.org/structure/7L4I; PPM1HDA-
LD), and 7n0z (https://www.rcsb.org/structure/7N0Z; MnPPM1HLD).
All primary data associated with each figure have been deposited in
the Zenodo data repository with a doi number https://doi.org/10.
5281/zenodo.5045023. The mass spectrometry proteomic data have
been deposited to the ProteomeXchange Consortium via the PRIDE
partner repository with the dataset identifier PXD026367 (https://
www.ebi.ac.uk/pride/archive/projects/PXD026367).
Expanded View for this article is available online.
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Note added in Proof
The recently reported AlphaFold predicted structure of human PPM1H (https://
alphafold.ebi.ac.uk/entry/Q9ULR3) (Jumper et al, Nature 2021, https://doi.org/
10.1038/s41586-021-03819-2) is very similar to that determined experimentally
in this study.
References
Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ,
Hung LW, Kapral GJ, Grosse-Kunstleve RW et al (2010) PHENIX: a
comprehensive Python-based system for macromolecular structure
solution. Acta Crystallogr D Biol Crystallogr 66: 213 – 221
Alessi DR, Sammler E (2018) LRRK2 kinase in Parkinson’s disease. Science 360:
36 – 37
Almo SC, Bonanno JB, Sauder JM, Emtage S, Dilorenzo TP, Malashkevich V,
Wasserman SR, Swaminathan S, Eswaramoorthy S, Agarwal R et al (2007)
Structural genomics of protein phosphatases. J Struct Funct Genomics 8:
121 – 140
Azeggagh S, Berwick DC (2021) The development of inhibitors of leucine-rich
repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson’s disease:
the current state of play. Br J Pharmacol 1 – 18. https://doi.org/10.1111/
bph15575
Baykov AA, Evtushenko OA, Avaeva SM (1988) A malachite green procedure
for orthophosphate determination and its use in alkaline phosphatase-
based enzyme immunoassay. Anal Biochem 171: 266 – 270
Berndsen K, Lis P, Yeshaw WM, Wawro PS, Nirujogi RS, Wightman M,
Macartney T, Dorward M, Knebel A, Tonelli F et al (2019) PPM1H
phosphatase counteracts LRRK2 signaling by selectively dephosphorylating
Rab proteins. Elife 8: e50416
Bradshaw N, Levdikov VM, Zimanyi CM, Gaudet R, Wilkinson AJ, Losick R
(2017) A widespread family of serine/threonine protein phosphatases
shares a common regulatory switch with proteasomal proteases. Elife 6:
e26111
Cabrita LD, Dai W, Bottomley SP (2006) A family of E. coli expression vectors
for laboratory scale and high throughput soluble protein production. BMC
Biotechnol 6: 12
Chen MJ, Dixon JE, Manning G (2017) Genomics and evolution of protein
phosphatases. Science Signaling 10: eaag1796
Chin-Sang ID, Spence AM (1996) Caenorhabditis elegans sex-determining
protein FEM-2 is a protein phosphatase that promotes male development
and interacts directly with FEM-3. Genes Dev 10: 2314 – 2325
Das AK, Helps NR, Cohen PT, Barford D (1996) Crystal structure of the protein
serine/threonine phosphatase 2C at 2.0 A resolution. EMBO J 15:
6798 – 6809
Debnath S, Kosek D, Tagad HD, Durell SR, Appella DH, Acevedo R, Grishaev A,
Dyda F, Appella E, Mazur SJ (2018) A trapped human PPM1A-
phosphopeptide complex reveals structural features critical for regulation
of PPM protein phosphatase activity. J Biol Chem 293: 7993 – 8008
Dhekne HS, Yanatori I, Gomez RC, Tonelli F, Diez F, Schule B, Steger M, Alessi
DR, Pfeffer SR (2018) A pathway for Parkinson’s disease LRRK2 kinase to
block primary cilia and Sonic hedgehog signaling in the brain. Elife 7:
e40202
Di Maio R, Hoffman EK, Rocha EM, Keeney MT, Sanders LH, De Miranda BR,
Zharikov A, Van Laar A, Stepan AF, Lanz TA et al (2018) LRRK2 activation
in idiopathic Parkinson’s disease. Sci Transl Med 10: eaar5429
Dominguez C, Boelens R, Bonvin AMJJ (2003) HADDOCK: a proteinprotein
docking approach based on biochemical or biophysical information. J Am
Chem Soc 125: 1731 – 1737
Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development
of Coot. Acta Crystallogr D Biol Crystallogr 66: 486 – 501
Fell MJ, Mirescu C, Basu K, Cheewatrakoolpong B, DeMong DE, Ellis JM, Hyde
LA, Lin Y, Markgraf CG, Mei H et al (2015) MLi-2, a potent, selective, and
centrally active compound for exploring the therapeutic potential and
safety of LRRK2 kinase inhibition. J Pharmacol Exp Ther 355: 397 – 409
ª 2021 The Authors EMBO reports e52675 | 2021 21 of 22
Dieter Waschb€usch et al EMBO reports
Gao C, Cao N, Wang Y (2021) Metal dependent protein phosphatase PPM
family in cardiac health and diseases. Cell Signall 85: 110061
Götze M, Iacobucci C, Ihling CH, Sinz A (2019) A simple cross-linking/mass
spectrometry workflow for studying system-wide protein interactions. Anal
Chem 91: 10236 – 10244
Götze M, Pettelkau J, Schaks S, Bosse K, Ihling CH, Krauth F, Fritzsche R, K€uhn
U, Sinz A (2012) StavroX—a software for analyzing crosslinked products in
protein interaction studies. J Am Soc Mass Spectrom 23: 76 – 87
Grzechnik AT, Newton AC (2016) PHLPPing through history: a decade in the
life of PHLPP phosphatases. Biochem Soc Trans 44: 1675 – 1682
He L, Diedrich J, Chu Y-Y, Yates JR (2015) Extracting accurate precursor
information for tandem mass spectra by RawConverter. Anal Chem 87:
11361 – 11367
Holm L (2020) DALI and the persistence of protein shape. Protein Sci 29:
128 – 140
Hutagalung AH, Novick PJ (2011) Role of Rab GTPases in membrane traffic
and cell physiology. Physiol Rev 91: 119 – 149
Iacobucci C, Götze M, Ihling CH, Piotrowski C, Arlt C, Sch€afer M, Hage C,
Schmidt R, Sinz A (2018) A cross-linking/mass spectrometry workflow
based on MS-cleavable cross-linkers and the MeroX software for studying
protein structures and protein–protein interactions. Nat Protoc 13:
2864 – 2889
Ito G, Katsemonova K, Tonelli F, Lis P, Baptista MAS, Shpiro N, Duddy G,
Wilson S, Ho P-L, Ho S-L et al (2016) Phos-tag analysis of Rab10
phosphorylation by LRRK2: a powerful assay for assessing kinase function
and inhibitors. Biochem J 473: 2671 – 2685
Kamada R, Kudoh F, Ito S, Tani I, Janairo JIB, Omichinski JG, Sakaguchi K
(2020) Metal-dependent Ser/Thr protein phosphatase PPM family:
evolution, structures, diseases and inhibitors. Pharmacol Ther 215: 107622
Linn TC, Pettit FH, Reed LJ (1969) Alpha-keto acid dehydrogenase complexes.
X. Regulation of the activity of the pyruvate dehydrogenase complex from
beef kidney mitochondria by phosphorylation and dephosphorylation. Proc
Natl Acad Sci USA 62: 234 – 241
Longo PA, Kavran JM, Kim M-S, Leahy DJ (2013) Chapter Eighteen - Transient
mammalian cell transfection with Polyethylenimine (PEI), In Methods in
enzymology, Lorsch J (ed), pp 227 – 240. Cambridge, MA: Academic Press
Maeda T, Wurgler-Murphy SM, Saito H (1994) A two-component system that
regulates an osmosensing MAP kinase cascade in yeast. Nature 369:
242 – 245
McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ
(2007) Phaser crystallographic software. J Appl Crystallogr 40: 658 – 674
Moore F, Weekes J, Hardie DG (1991) Evidence that AMP triggers
phosphorylation as well as direct allosteric activation of rat liver AMP-
activated protein kinase. Eur J Biochem 199: 691 – 697
Osawa J, Akizuki K, Kashimura A, Ueta S, Nakatani M, Inui Y, Shigeri Y, Ishida
A, Kameshita I, Sueyoshi N (2020) Dual phosphorylation of protein
phosphatase PPM1H promotes dephosphorylation of Smad1 in cellulo.
Biochem Biophys Res Comm 530: 513 – 519
Pan C, Tang J-Y, Xu Y-F, Xiao P, Liu H-D, Wang H-A, Wang W-B, Meng F-G,
Yu X, Sun J-P (2015) The catalytic role of the M2 metal ion in PP2Ca. Sci
Rep 5: 8560
Pan D, Brockmeyer A, Mueller F, Musacchio A, Bange T (2018) Simplified
protocol for cross-linking mass spectrometry using the MS-Cleavable
Cross-linker DSBU with efficient cross-link identification. Anal Chem 90:
10990 – 10999
Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC,
Ferrin TE (2004) UCSF Chimera—a visualization system for exploratory
research and analysis. J Comput Chem 25: 1605 – 1612
Pullen KE, Ng H-L, Sung P-Y, Good MC, Smith SM, Alber T (2004) An alternate
conformation and a third metal in PstP/Ppp, the M. tuberculosis PP2C-
family Ser/Thr protein phosphatase. Structure 12: 1947 – 1954
Rantanen MK, Lehtiö L, Rajagopal L, Rubens CE, Goldman A (2007) Structure
of Streptococcus agalactiae serine/threonine phosphatase. FEBS J 274:
3128 – 3137
Schlicker C, Fokina O, Kloft N, Gr€une T, Becker S, Sheldrick GM, Forchhammer
K (2008) Structural analysis of the PP2C phosphatase tPphA from
Thermosynechococcus elongatus: a flexible flap subdomain controls access
to the catalytic site. J Mol Biol 376: 570 – 581
Sonn-Segev A, Belacic K, Bodrug T, Young G, VanderLinden RT, Schulman BA,
Schimpf J, Friedrich T, Dip PV, Schwartz TU et al (2020) Quantifying the
heterogeneity of macromolecular machines by mass photometry. Nat
Commun 11: 1772
Steger M, Diez F, Dhekne HS, Lis P, Nirujogi RS, Karayel O, Tonelli F, Martinez
TN, Lorentzen E et al (2017) Systematic proteomic analysis of LRRK2-
mediated Rab GTPase phosphorylation establishes a connection to
ciliogenesis. eLife 6: e31012
Steger M, Tonelli F, Ito G, Davies P, Trost M, Vetter M, Wachter S, Lorentzen E,
Duddy G, Wilson S et al (2016) Phosphoproteomics reveals that Parkinson’s
disease kinase LRRK2 regulates a subset of Rab GTPases. Elife 5: e12813
Stern A, Privman E, Rasis M, Lavi S, Pupko T (2007) Evolution of the
metazoan protein phosphatase 2C superfamily. J Mol Evol 64: 61 – 70
Su J, Forchhammer K (2013) Determinants for substrate specificity of the
bacterial PP2C protein phosphatase tPphA from Thermosynechococcus
elongatus. FEBS J 280: 694 – 707
Vassylyev DG, Symersky J (2007) Crystal structure of pyruvate dehydrogenase
phosphatase 1 and its functional implications. J Mol Biol 370: 417 – 426
Waschb€usch D, Khan AR (2021) Protein Data Bank 7thLWB (https://www.rcsb.
org/structure/7thLWB). [DATASET]
Waschb€usch D, Purlyte E, Pal P, McGrath E, Alessi DR, Khan AR (2020)
Structural basis for Rab8a recruitment of RILPL2 via LRRK2
phosphorylation of switch 2. Structure 28: 406 – 417.e406
Waschb€usch D, Purlyte E, Khan AR (2021) Dual arginine recognition of LRRK2
phosphorylated Rab GTPases. Biophys J 120: 1846 – 1855
Young G, Hundt N, Cole D, Fineberg A, Andrecka J, Tyler A, Olerinyova A,
Ansari A, Marklund EG, Collier MP et al (2018) Quantitative mass imaging
of single biological macromolecules. Science 360: 423 – 427
van Zundert GCP, Rodrigues JPGLM, Trellet M, Schmitz C, Kastritis PL, Karaca
E, Melquiond ASJ, van Dijk M, de Vries SJ, Bonvin AMJJ (2016) The
HADDOCK2.2 web server: user-friendly integrative modeling of
biomolecular complexes. J Mol Biol 428: 720 – 725
License: This is an open access article under the
terms of the Creative Commons Attribution License,
which permits use, distribution and reproduction in
any medium, provided the original work is properly
cited.
22 of 22 EMBO reports e52675 | 2021 ª 2021 The Authors
EMBO reports Dieter Waschb€usch et al
